Comparison

ESMO Interactive Guidelines vs Chronic Lymphocytic Leukemia

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

ESMO Interactive Guidelines

Access concise, practical treatment recommendations based on the latest scientific research. This app provides interactive tools, algorithms, and calculators to support healthcare professionals in decision-making and guideline navigation.

Highlights
  • Concise treatment recommendations
  • Interactive decision-making tools
  • Treatment algorithms and calculators
  • Keyword search functionality
  • Bookmarking and note-taking
  • News and push notifications
Features
Read full description

The European Society for Medical Oncology (ESMO) guidelines are developed by experts. They are concise, practical and offer users treatment recommendations that are based on the latest scientific research. This application uses interactive tools to support decision making and help the user navigate the guidelines easily, so they can access the information they require quickly. Each guideline offers best practice recommendations for screening, diagnosis, staging, treatment and follow up. The ESMO Interactive Guidelines application ensures the user has the highest standard of information at their figure tips. A variety of interactive treatment algorithms, tables, calculators and scores can be utilised to assist the treating doctor. The user can also perform key word searches, bookmark useful pages, add notes and email pages to colleagues or patients. The app features news and push notifications. Disclaimer: The app is intended to assist healthcare professionals and allied healthcare professionals as an educational tool to provide information that may support them in providing care to patients. Patients or other community members using this app shall do so only after consultation with a health professional and shall not mistake these guidelines as professional medical advice. These guidelines must not substitute seeking professional medical and health advice from a health professional. These guidelines may not apply to all situations and shall be interpreted in the light of specific clinical situations and resource availability. It is up to every clinician to adapt these guidelines to local regulations and to each patient’s individual circumstances and needs. The app contains information obtained from authentic and highly regarded sources (http://www.esmo.org). Although every effort has been made to ensure that treatment and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician.This application is updated regularly with more tumour types, guidelines and interactive tools.

About

Chronic Lymphocytic Leukemia

This clinical decision support tool provides healthcare professionals with evidence-based medical content for managing Chronic Lymphocytic Leukemia. It uses AI to answer natural language questions, offering confidence-rated insights on diagnosis, treatment, and care.

Highlights
  • AI-powered clinical decision support
  • Evidence-based medical content
  • Voice-enabled natural language questions
  • Diagnosis, treatment, and care management topics
  • Case studies, videos, and interviews
  • Continuing medical education credit (CME/CE)
  • Patient education resources
Features
Read full description

@Point of Care™ with Ask Cognitive AI is a clinical decision-making mobile platform. Chronic Lymphocytic Leukemia @Point of Care™ provides a streamlined clinical decision support tool for clinicians to obtain content when it is needed—enabling better decisions, better outcomes, and better care. With Cognitive AI, clinicians use @Point of Care™ to easily access curated, evidence-based, and disease-specific medical content. Clinicians navigate content by asking voice-enabled natural language questions. With Cognitive AI, confidence-rated answers to efficiently incorporate best treatment options happen more quickly and decisions are made faster to improve patient outcomes at the point of care. Chronic Lymphocytic Leukemia @Point of Care™ is designed to: • Support discovery and practice change • Provide relevant, evidence-based disease-specific medical content • Improve patient outcomes at the point of care Features: • Continually updated Chronic Lymphocytic Leukemia content • Topics in diagnosis, treatment, and care management developed with expert physician authors • Case studies, videos, and interviews • Access to actionable patient-recorded data • Detailed reference list with access to original sources • Continuing medical education credit (CME/CE) • Surveys and peer polling • Patient education resources to share with patients

Screenshots

ESMO Interactive Guidelines4 screens
Chronic Lymphocytic Leukemia4 screens

Verdict

The call

The clearest difference is ratings volume: ESMO Interactive Guidelines at 157 against Chronic Lymphocytic Leukemia's 2. ESMO Interactive Guidelines also leads on iOS requirement (12.0 vs 14.0). Chronic Lymphocytic Leukemia's advantage is update cadence (every 2 months vs every 6 months). On price, rating, ads and in-app purchases there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

Chronic Lymphocytic Leukemia holds the better App Store score, 5.0 against 4.8. That said, the two scores are not equally well evidenced: ESMO Interactive Guidelines has 157 ratings behind it against 2, so its average is the more settled of the two.

UpkeepUpdate frequency

ESMO Interactive Guidelines ships an update every 6 months, Chronic Lymphocytic Leukemia every 2 months. The most recent releases landed on October 29, 2026 and October 9, 2026 respectively.

Scorecard3 real differences · 7 level
ESMO Interactive Guidelines versus Chronic Lymphocytic Leukemia: the parameters behind the verdict, then further details
ParameterESMO Interactive GuidelinesChronic Lymphocytic Leukemia
PriceFreeFree
Rating4.8 (157 ratings)5.0 (2 ratings) — better
Positive reviews66.7% of reviews—
Number of ratings157 — better2
Update frequencyEvery 6 monthsEvery 2 months — better
AdsNoNo
In-app purchasesNoNo
MonetizationFreeFree
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS12.0 — better14.0
Further details — not scored
Size195 MB23 MB
Age rating12+12+
DeveloperEuropean Society for Medical Oncology - ESMO@Point of Care

Customer experience

ESMO Interactive Guidelines

All ratings150 ratings
Positive96.7%
Neutral2.0%
Negative1.3%
Written reviews6 reviews
Positive66.7%
Neutral0.0%
Negative33.3%

Chronic Lymphocytic Leukemia

All ratings2 ratings
Positive100.0%
Neutral0.0%
Negative0.0%

In-app purchases

None

ESMO Interactive Guidelines

No in-app purchases

None

Chronic Lymphocytic Leukemia

No in-app purchases

Questions

Is ESMO Interactive Guidelines free?
ESMO Interactive Guidelines is free to download, with no in-app purchases.
Is Chronic Lymphocytic Leukemia free?
Chronic Lymphocytic Leukemia is free to download, with no in-app purchases.
Which has better reviews, ESMO Interactive Guidelines or Chronic Lymphocytic Leukemia?
Chronic Lymphocytic Leukemia is rated higher. ESMO Interactive Guidelines averages 4.8 out of 5 from 157 ratings, while Chronic Lymphocytic Leukemia averages 5.0 from 2 ratings.
Do ESMO Interactive Guidelines or Chronic Lymphocytic Leukemia have ads?
Neither ESMO Interactive Guidelines nor Chronic Lymphocytic Leukemia shows ads.
Which is updated more often, ESMO Interactive Guidelines or Chronic Lymphocytic Leukemia?
ESMO Interactive Guidelines ships an update every 6 months, and Chronic Lymphocytic Leukemia every 2 months. Most recently, ESMO Interactive Guidelines was updated on October 29, 2026 and Chronic Lymphocytic Leukemia on October 9, 2026.

Other comparisons